New Inhaled Medicines for Tuberculosis
Inhalational therapy with spectinamides within new regimens of TB therapy
This research looks for new, easier, and safer ways to treat tuberculosis by using inhaled medicines.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Colorado State University NIH-funded |
| Lab location | 1 site (Fort Collins, United States) |
| Project ID | NIH-11132980 on NIH RePORTER |
What this research studies
We are working to find shorter, simpler, and safer treatments for tuberculosis (TB) that have fewer pills and fewer side effects. Current successful TB treatments can sometimes cause unpleasant side effects, especially with long-term use. Our goal is to replace one of these problematic drugs with a new inhaled medicine called spectinamide, which has shown good safety and effectiveness in early tests. We plan to combine this inhaled medicine with other existing TB drugs to create new treatment plans that could be given for a shorter time, possibly 2-3 months.
Who could benefit from this research
Good fit: Patients with tuberculosis, especially those with drug-resistant forms, could potentially benefit from future treatments developed from this research.
Not a fit: Patients without tuberculosis would not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to new tuberculosis treatments that are shorter, simpler, and have fewer side effects for patients.
How similar studies have performed: Previous multi-drug regimens for TB have shown success, but often come with significant side effects, making this approach of finding safer alternatives a continuation of successful strategies.
Where this research is happening
Fort Collins, United States
- Colorado State University — Fort Collins, United States (Active)
Researchers
- Principal investigator: Gonzalez-Juarrero, Mercedes — Colorado State University
- Study coordinator: Gonzalez-Juarrero, Mercedes
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.